Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 259

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 259
---
 sales, commercial and marketing, technology, and
finance and administration teams and refine Longevity’s operational, financial and risk management controls and reporting systems
and procedures as it grows; and (v) factors outside of the parties’ control, such as climate risks, fluctuations in interest,
inflation and exchange rates and the potential negative impact of logistics and suppliers disruptions from trade wars, advancement
of artificial intelligence, uncertainty in the Middle East and the Russia-Ukraine conflict.

In this regard, FutureTech
Board also considered risks relating to obtaining and maintaining necessary regulatory approvals for commercializing Longevity’s
treatments, the effect of competing clinical, technological and market developments, the outcomes of ongoing and future clinical trials
relating to Longevity’s pipeline and rights to use and the ability to protect intellectual property used in Longevity’s business
and products, among others and the combined company realizing the anticipated benefits of the Business Combination on the timeline expected
or at all, including due to factors outside of the parties’ control such as new regulatory requirements or changes to existing
regulatory requirements (or feedback from regulatory authorities that requires Longevity to modify the design of its clinical trials)
and changes in the market for biotechnology generally. The FutureTech Board considered that the failure of any of these activities to
be completed successfully may decrease the actual benefits of the Business Combination and that FutureTech stockholders may not fully
realize these benefits to the extent that they expected following the completion of the Business Combination. For additional description
of these risks, please see the section entitled “Risk Factors.”

Competition.
Longevity’s industry are rapidly evolving and Longevity will face competitions from a variety of companies in the same industry.

Business Plan and Projections May Not be Achieved. The risk that Longevity may not be able to execute on its business plan on time or at
all, or realize the financial performance as set forth in the financial projections presented to FutureTech’s management and board,
and the risk that Longevity may need to raise additional capital to achieve its business plan.

| 131 |

Limitations of Review. The fact that FutureTech’s management, board and advisors reviewed only certain materials in connection with
their due diligence review of Longevity and Targets and may not have properly evaluated Longevity’s and Targets’ business.

Liquidation.
The risks and costs to FutureTech if the Business Combination is not completed, including the risk of diverting management focus and resources
from other business combination opportunities, which could result in FutureTech being unable to